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At the bone marrow transplantation center of the San Mar-
tino Hospital (Genoa), we observed an increase in the rate
of patients with positive Platelia Aspergillus (PA; Bio-Rad)
test results, from 10% (38 of 386 patients) in the period from
January 1999 through January 2003 to 36% (21 of 59 pa-
tients) in the period from February 2003 through May 2003.
Positivity was significantly ( ) associated with the ad-P ! .001
ministration of piperacillin-tazobactam (PT) (17 [74%] of 23
patients who received PT had positive results vs. 4 [11%] of
36 who did not receive PT). Multivariate analysis found ad-
ministration of PT ( ; ) and underlying dis-2x p 34.7 P ! .001
ease ( ; ) to be associated with PA positivity.2x p 21.14 P ! .001
Of 15 PT batches tested, 12 had positive PA test results.
Despite the availability of new and promising antifungal drugs,
the mortality rate among patients with invasive aspergillosis
(IA) remains high [1]. This is likely due, at least in part, to the
frequent impossibility of obtaining a reliable diagnosis at an
early stage of the disease and the consequent delays in starting
treatment. In recent years, some progress in early diagnosis has
been reported with the combined use of high-resolution CT
and serial screening for circulating Aspergillus galactomannan,
a fungal exoantigen that is part of the fungal cell wall [2–4].
Although contrasting results have been reported, sensitivity and
Received 1 October 2003; accepted 15 December 2003; electronically published 27 February
2004.
Financial support: This research was supported in part by the Ministero della Sanita`, Istituti
di Ricerca a Carattere Scientifico (Progetto Finalizzato BS2); P.C. was supported by the
Coordenac¸a˜o de Aperfeic¸oamento de Pessoal de Nivel Superior Foundation, Ministry of
Education of Brazil.
Reprints or correspondence: Dr. Claudio Viscoli, Infectious Disease Unit, National Institute
for Cancer Research, Largo R. Benzi 10, 16132 Genoa, Italy (viscolic@unige.it).
Clinical Infectious Diseases 2004; 38:913–6
 2004 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2004/3806-0025$15.00
specificity appear to be fairly good, and the test results are
sometimes positive before the onset of symptoms or radiolog-
ical abnormalities. The test was recently approved by the US
Food and Drug Administration. At the Bone Marrow Trans-
plantation Center of the San Martino Hospital (Genoa), twice-
weekly patient monitoring with the Platelia Aspergillus (PA; Bio-
Rad) test (performed at the Infectious Disease Unit of the
National Institute for Cancer Research [Genoa]) has been com-
mon practice since 1999. In April 2003, in the setting of a
routine internal quality control assessment, we realized that the
proportion of positive samples was increasing, and we decided
to undergo a thorough reevaluation process to learn whether
the increase was related to an aspergillosis outbreak or to some
interaction causing false-positive results.
Methods. The characteristics of the PA test have been de-
scribed elsewhere [5–9]. We process serum samples according
to manufacturer’s instructions, and the ELISA results are tab-
ulated as the index between the optical density of the sample
tested and the optical density of the threshold positive control.
At least 2 subsequent positive test results are required for a
patient to be considered positive for IA. The cutoff point we
used for defining a positive sample decreased over the years,
from 1.5 to 0.7, in accordance with published indications [10–
12]. For the purpose of the present quality control, a threshold
of 0.7 was used. To evaluate whether or not we were actually
facing an increase in the proportion of positive results with
respect to our normal values, we calculated the monthly dis-
tribution of positive results for the period from January 1999
through May 2003. We then looked at the clinical history of
patients with2 consecutive positive test results in the previous
4 months of observation, and we classified each case as proven,
probable, or possible aspergillosis, on the basis of the criteria
established by the European Organization for Research and
Treatment of Cancer–Mycoses Study Group [13], with and
without considering the PA test result. Finally, we looked at
major differences in laboratory and clinical procedures, and we
performed a multivariate analysis of baseline clinical factors
that might have been associated with the chance of having a
positive result.
Results. From January 1999 through May 2003, a total of
420 consecutive patients were sequentially monitored twice
weekly with the PA test. A total of 4702 serum samples were
tested during this period, with a median of 7 specimens per
patient (range, 1–64) and 85 specimens per month (range, 35–
146). As shown in figure 1, in the period from January 1999
through January 2003, the median positivity rate per month
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Figure 1. Percentage of samples per month with positive Platelia Aspergillus (PA) test results, January 1999–May 2003. All samples were obtained
from patients who underwent bone marrow transplantation. Bars indicate 95% CIs.
in terms of blood specimens was 9% (range, 0–18%) and in-
creased to 24% (range, 20–44%) in the period from February
2003 through May 2003. Similarly, the overall proportion of
patients classified as positive for IA according to the PA test
(i.e., those with 2 samples with positive PA test results ob-
tained within 7 days) increased from 10% (38 of 386 patients)
in the first study period to 36% (21 of 59) in the second study
period (25 patients overlapped in the 2 periods). Possible ex-
planations for this phenomenon included an outbreak of IA,
a technical problem related to the test itself, or an interaction
with unknown factors able to cause false-positive results.
To rule out the possibility of an aspergillosis outbreak, we
reviewed the clinical histories of the 21 patients with positive
PA test results during the period from February 2003 through
May 2003, using the standard definitions for invasive fungal
infection of the EORTC-MSG consensus group [13]. Overall,
no patient had proven aspergillosis, 4 had probable aspergillosis,
and 17 had possible aspergillosis. However, not taking into
account the results of the PA test, 3 of the 4 cases of probable
aspergillosis and all of the cases of possible aspergillosis would
have been downgraded to possible aspergillosis or no asper-
gillosis, respectively. Indeed, the 17 patients with possible as-
pergillosis had no symptoms whatsoever. This led us to exclude
the possibility that the increase in the rate of positive PA test
results was actually due to an aspergillosis outbreak.
To rule out the possibility of a technical dysfunction, we
reviewed all laboratory procedures. No methodological change
had been introduced. In addition, there was no difference in
the way that the 2 PA batches that were in use during the study
period performed. Finally, the first batch had been in use since
January 2003, when the proportion of positive samples was
within our normal values (i.e., 0%–18%).
As for clinical factors, patients were treated in the same
rooms during the possible outbreak that they had been treated
in earlier, and no change had been made in their parenteral or
enteral nutrition or immunosuppressive regimens. Similarly, no
change in the usual distribution of pathogens that cause in-
fection was documented, and, in particular, no pathogen known
to cause false-positive PA test results was isolated [14–16]. How-
ever, an important clinical factor was detected. Beginning in
February 2003, because of an increasing incidence of pipera-
cillin-sensitive Enterococcus faecalis bacteremia, the usual em-
pirical antibiotic regimen (ceftazidime and amikacin) was grad-
ually replaced by a new regimen (piperacillin-tazobactam and
amikacin) to improve the antistreptococcal coverage. The pro-
portion of patients positive for IA according to the PA test (i.e.,
those with 2 positive PA test results within 7 days) was 74%
(17 of 23) among those receiving piperacillin-tazobactam, com-
pared with 11% (4 of 36) among those not receiving pipera-
cillin-tazobactam ( ). For those receiving piperacillin-P ! .001
tazobactam, blood samples were obtained during treatment or
within 24 h after discontinuation of treatment. A multivariate
analysis of baseline factors potentially able to affect PA test
results was performed. The probability of having a positive
result in the 59 patients monitored in the period from February
2003 through May 2003 was modeled by means of multivariate
logistic regression as a function of several variables, including
the underlying disease (acute leukemia, chronic leukemia, my-
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eloma and lymphoma, aplastic anemia, or other), type of trans-
plantation (HLA identical, mismatched/unrelated, autologous,
or other), status of the underlying disease (first remission, sec-
ond or third remission, or relapse), use of total body irradiation
(yes or no), use of thymoglobulins (yes or no), type of graft-
versus-host disease prophylaxis (methotrexate and cyclophos-
phamide or other), age (continuous variable), sex, type of em-
pirical antibiotic therapy, type of stem cells used (peripheral or
BMT), and donor and/or recipient CMV status. The only 2
variables significantly associated with the odds of a positive test
result were underlying disease ( ; ) and type2x p 21.14 P ! .001
of empirical antibiotic therapy ( ; ).2x p 34.7 P ! .001
Thirty piperacillin-tazobactam vials from 15 different batches
taken from the hospital pharmacy were then tested with the
PA test. The drug was diluted according to manufacturer’s in-
structions (4.5 g/100mL NaCl 0.9%), and the test was per-
formed on both the diluted and the undiluted solutions (NaCl
0.9%) with the same methodology used for serum specimens.
Overall, 12 (80%) of 15 batches (including 2 batches that were
being used in the bone marrow transplantation unit during the
study period) had positive PA test results, with a median gal-
actomannan index of 4.6 (range, 1.3–5.7), and 3 batches had
negative PA test results, with a median index of 0.16 (range,
0.11–0.19). All PA tests performed on the NaCl 0.9% dilutent
had negative results.
Discussion. The detection of circulating galactomannan in
serum samples obtained from patients who are at high risk for
fungal infections is an important advance in the diagnosis of
invasive aspergillosis in patients who receive bone marrow
transplantation. The sensitivity and specificity of the test varies
according to several factors, including the number of samples
obtained from each patient, the extent of fungal angioinvasion,
and the concomitant presence in the patient of cross-reacting
substances or other infections. Indeed, cross-reactions of the
monoclonal antibody (MAb) EB-A2, used in this test, have been
described with other organisms (such as Fusarium oxysporum,
Rhodotorula rubra [14], Trichophyton rubrum, Trichophyton in-
terdigitalis [15], Penicillium chrysogenum, Penicillium digitatum,
Paecilomices variotii, and Alternaria species [16]) and also with
infant milk formulas [17], cyclophosphamide [18], and food
[19, 20]. In the clinical field, false-positive results have been
especially frequent among premature infants [21]. In 1997, An-
sorg et al. [19] studied the in vitro specificity of the latex ag-
glutination test Pastorex Aspergillus, which employs the same
MAb EB-A2 as the PA test. Among other substances, they also
tested piperacillin and amoxicillin and found that both anti-
biotics sometimes had positive latex test results. It is worth
noting that the latex test was detecting only 10 ng/mL of gal-
actomannan in serum vs. 1 ng/mL of galactomannan detected
by the ELISA test. In the present study, we found that the
administration of piperacillin-tazobactam as empirical anti-
bacterial therapy in recipients of bone marrow transplantation
is associated with a high incidence of false-positive PA test
results. The test also produced positive results for 12 of 15
batches of piperacillin-tazobactam used at the Bone Marrow
Transplantation Center of the Department of Hematology, San
Martino Hospital (Genoa), at the time of the study. Piperacillin
is a semisynthetic drug derived from molds of the genus Pen-
icillium, a filamentous fungus that contains galactomannan in
the cell wall [15]. As has already been suggested [19], it may
be reasonable to think that galactomannan (or similar moieties
bearing the epitope reacting with MAb EB-A2) is carried
through the production process of this antibiotic into batches
designed for therapeutic use.
In our epidemiological situation, piperacillin-tazobactam is
an important drug for the management of febrile neutropenia.
For this reason, we have decided to continue to use the drug,
although only in the preengraftment period, when the risk of
aspergillosis and consequent need for galactomannan moni-
toring are lower and the risk of severe bacterial infection is
higher. With the gradual introduction of this new antibiotic
policy, the positivity rate decreased from 45% in May 2003 to
29% in June 2003 and to 5% in July 2003.
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